Regulators have already extended GLP-1 approvals beyond weight and glucose management into cardiovascular risk reduction and sleep apnea, and ongoing trials are examining kidney disease, liver disease, and other conditions
Exenatide (Byetta, Bydureon) : A medication primarily used to manage type 2 diabetes
Plateaus typically occur after an initial period of consistent weight loss and represent a normal physiological adaptation rather than treatment failure
Subsequently, GLP1-RAs induce growth hormone secretion, stimulating the production of insulin-like growth factor-1 (IGF-1) by the liver
This next-generation incretin mimetic is at the forefront of research in obesity, insulin resistance, and type 2 diabetes
(PubMed) Rohan TE, Jain MG, Howe GR, Miller AB